Immatics N.V. Shares Positive Phase 1 Data for IMA401
Ticker: IMTX · Form: 6-K · Filed: Sep 16, 2024 · CIK: 1809196
Sentiment: bullish
Topics: clinical-trial-data, oncology, bispecific-antibody
TL;DR
Immatics drops Phase 1 data for IMA401, showing promise in cancer treatment.
AI Summary
On September 16, 2024, Immatics N.V. announced proof-of-concept clinical data from its Phase 1 trial for TCER® IMA401. This novel bispecific T cell engager targets MAGEA4 and MAGEA8 peptides presented by HLA-A*02. The data supports the potential of IMA401 in treating various cancers.
Why It Matters
Positive clinical data for IMA401 could advance Immatics' pipeline and offer a new therapeutic option for patients with MAGEA4/MAGEA8-expressing cancers.
Risk Assessment
Risk Level: medium — Clinical trial data is inherently uncertain, and further development is required to confirm efficacy and safety.
Key Players & Entities
- Immatics N.V. (company) — Registrant and developer of IMA401
- IMA401 (drug) — TCR bispecific molecule in Phase 1 trial
- TCER® (drug_platform) — Technology platform for IMA401
- MAGEA4 (target) — Target antigen for IMA401
- MAGEA8 (target) — Target antigen for IMA401
- HLA-A*02 (biomarker) — Presentation molecule for target antigens
FAQ
What specific proof-of-concept clinical data was released for TCER® IMA401?
The filing states that proof-of-concept clinical data was released, but does not specify the exact metrics or results within the provided text.
What is the primary mechanism of action for TCER® IMA401?
TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8.
What is the target indication for IMA401 based on the provided information?
The filing indicates IMA401 targets MAGEA4 and MAGEA8 with high target copy numbers on various cancers, suggesting broad applicability.
What is the current stage of development for IMA401?
IMA401 is currently in an ongoing Phase 1 trial.
When was this information filed with the SEC?
This Form 6-K was filed on September 16, 2024.
Filing Stats: 1,786 words · 7 min read · ~6 pages · Grade level 13.5 · Accepted 2024-09-16 07:01:18
Key Financial Figures
- $150 million — obligated to refund BMS any part of the $150 million upfront payment received under the coll
Filing Documents
- dp217895_6k.htm (6-K) — 28KB
- dp217895_ex9901.htm (EX-99.1) — 34KB
- dp217895_ex9902.htm (EX-99.2) — 53KB
- dp217895_ex9903.htm (EX-99.3) — 104KB
- ex9902_001.jpg (GRAPHIC) — 422KB
- ex9902_002.jpg (GRAPHIC) — 883KB
- ex9902_003.jpg (GRAPHIC) — 313KB
- ex9902_004.jpg (GRAPHIC) — 329KB
- ex9902_005.jpg (GRAPHIC) — 509KB
- ex9902_006.jpg (GRAPHIC) — 419KB
- ex9902_007.jpg (GRAPHIC) — 370KB
- ex9902_008.jpg (GRAPHIC) — 534KB
- ex9902_009.jpg (GRAPHIC) — 335KB
- ex9902_010.jpg (GRAPHIC) — 467KB
- ex9902_011.jpg (GRAPHIC) — 260KB
- ex9902_012.jpg (GRAPHIC) — 444KB
- ex9902_013.jpg (GRAPHIC) — 403KB
- ex9902_014.jpg (GRAPHIC) — 428KB
- ex9902_015.jpg (GRAPHIC) — 458KB
- ex9902_016.jpg (GRAPHIC) — 258KB
- ex9902_017.jpg (GRAPHIC) — 247KB
- ex9902_018.jpg (GRAPHIC) — 432KB
- ex9902_019.jpg (GRAPHIC) — 399KB
- ex9902_020.jpg (GRAPHIC) — 301KB
- ex9902_021.jpg (GRAPHIC) — 279KB
- ex9902_022.jpg (GRAPHIC) — 230KB
- ex9902_023.jpg (GRAPHIC) — 434KB
- ex9902_024.jpg (GRAPHIC) — 299KB
- ex9902_025.jpg (GRAPHIC) — 481KB
- ex9902_026.jpg (GRAPHIC) — 465KB
- ex9902_027.jpg (GRAPHIC) — 452KB
- ex9902_028.jpg (GRAPHIC) — 471KB
- ex9902_029.jpg (GRAPHIC) — 307KB
- ex9902_030.jpg (GRAPHIC) — 220KB
- ex9903_001.jpg (GRAPHIC) — 340KB
- ex9903_002.jpg (GRAPHIC) — 882KB
- ex9903_003.jpg (GRAPHIC) — 227KB
- ex9903_004.jpg (GRAPHIC) — 399KB
- ex9903_005.jpg (GRAPHIC) — 361KB
- ex9903_006.jpg (GRAPHIC) — 291KB
- ex9903_007.jpg (GRAPHIC) — 433KB
- ex9903_008.jpg (GRAPHIC) — 492KB
- ex9903_009.jpg (GRAPHIC) — 289KB
- ex9903_010.jpg (GRAPHIC) — 337KB
- ex9903_011.jpg (GRAPHIC) — 191KB
- ex9903_012.jpg (GRAPHIC) — 420KB
- ex9903_013.jpg (GRAPHIC) — 361KB
- ex9903_014.jpg (GRAPHIC) — 415KB
- ex9903_015.jpg (GRAPHIC) — 681KB
- ex9903_016.jpg (GRAPHIC) — 358KB
- ex9903_017.jpg (GRAPHIC) — 355KB
- ex9903_018.jpg (GRAPHIC) — 343KB
- ex9903_019.jpg (GRAPHIC) — 458KB
- ex9903_020.jpg (GRAPHIC) — 411KB
- ex9903_021.jpg (GRAPHIC) — 331KB
- ex9903_022.jpg (GRAPHIC) — 214KB
- ex9903_023.jpg (GRAPHIC) — 536KB
- ex9903_024.jpg (GRAPHIC) — 413KB
- ex9903_025.jpg (GRAPHIC) — 361KB
- ex9903_026.jpg (GRAPHIC) — 345KB
- ex9903_027.jpg (GRAPHIC) — 346KB
- ex9903_028.jpg (GRAPHIC) — 306KB
- ex9903_029.jpg (GRAPHIC) — 440KB
- ex9903_030.jpg (GRAPHIC) — 200KB
- ex9903_031.jpg (GRAPHIC) — 295KB
- ex9903_032.jpg (GRAPHIC) — 421KB
- ex9903_033.jpg (GRAPHIC) — 330KB
- ex9903_034.jpg (GRAPHIC) — 297KB
- ex9903_035.jpg (GRAPHIC) — 261KB
- ex9903_036.jpg (GRAPHIC) — 338KB
- ex9903_037.jpg (GRAPHIC) — 306KB
- ex9903_038.jpg (GRAPHIC) — 210KB
- ex9903_039.jpg (GRAPHIC) — 538KB
- ex9903_040.jpg (GRAPHIC) — 351KB
- ex9903_041.jpg (GRAPHIC) — 423KB
- ex9903_042.jpg (GRAPHIC) — 370KB
- ex9903_043.jpg (GRAPHIC) — 539KB
- ex9903_044.jpg (GRAPHIC) — 343KB
- ex9903_045.jpg (GRAPHIC) — 266KB
- ex9903_046.jpg (GRAPHIC) — 447KB
- ex9903_047.jpg (GRAPHIC) — 431KB
- ex9903_048.jpg (GRAPHIC) — 207KB
- ex9903_049.jpg (GRAPHIC) — 395KB
- ex9903_050.jpg (GRAPHIC) — 261KB
- ex9903_051.jpg (GRAPHIC) — 206KB
- ex9903_052.jpg (GRAPHIC) — 337KB
- ex9903_053.jpg (GRAPHIC) — 302KB
- ex9903_054.jpg (GRAPHIC) — 197KB
- ex9903_055.jpg (GRAPHIC) — 283KB
- ex9903_056.jpg (GRAPHIC) — 406KB
- ex9903_057.jpg (GRAPHIC) — 465KB
- ex9903_058.jpg (GRAPHIC) — 271KB
- ex9903_059.jpg (GRAPHIC) — 324KB
- ex9903_060.jpg (GRAPHIC) — 344KB
- ex9903_061.jpg (GRAPHIC) — 246KB
- ex9903_062.jpg (GRAPHIC) — 282KB
- ex9903_063.jpg (GRAPHIC) — 227KB
- ex9903_064.jpg (GRAPHIC) — 515KB
- ex9903_065.jpg (GRAPHIC) — 412KB
- ex9903_066.jpg (GRAPHIC) — 307KB
- ex9903_067.jpg (GRAPHIC) — 378KB
- ex9903_068.jpg (GRAPHIC) — 316KB
- ex9903_069.jpg (GRAPHIC) — 196KB
- ex9903_070.jpg (GRAPHIC) — 437KB
- ex9903_071.jpg (GRAPHIC) — 214KB
- ex9903_072.jpg (GRAPHIC) — 338KB
- image_003.jpg (GRAPHIC) — 4KB
- image_073.jpg (GRAPHIC) — 108KB
- image_074.jpg (GRAPHIC) — 76KB
- image_075.jpg (GRAPHIC) — 85KB
- 0000950103-24-013585.txt ( ) — 52141KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMATICS N.V. Date: September 16, 2024 By: /s/ Harpreet Singh Name: Harpreet Singh Title: Chief Executive Officer